Analysts Offer Predictions for COYA Q1 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Coya Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.50) for the quarter. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.93) EPS.

A number of other research firms have also recently commented on COYA. D. Boral Capital reiterated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, May 13th.

Coya Therapeutics Stock Down 3.2%

Coya Therapeutics stock opened at $5.67 on Tuesday. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24. The firm has a market capitalization of $94.83 million, a PE ratio of -8.72 and a beta of 0.49. The firm’s 50-day simple moving average is $6.01 and its 200 day simple moving average is $6.15.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $257.88 million during the quarter, compared to analyst estimates of $2.63 million.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. DME Capital Management LP boosted its holdings in Coya Therapeutics by 29.2% in the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after purchasing an additional 372,414 shares during the period. AIGH Capital Management LLC increased its holdings in shares of Coya Therapeutics by 85.0% during the fourth quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock valued at $6,883,000 after purchasing an additional 551,725 shares during the period. CM Management LLC grew its position in Coya Therapeutics by 25.0% in the 1st quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,294,000 after buying an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics in the 1st quarter worth approximately $1,083,000. Finally, Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after purchasing an additional 8,267 shares during the period. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.